# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
– Collaboration advancing Palisade Bio's precision medicine approach through access to cutting-edge expertise and tools in ...
PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposureCompany on track to comm...
Data presented at Digestive Disease Week (DDW) 2024Preclinical data demonstrate PALI-2108 to be safe, effective, and well toler...
Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(4.59) per share which missed the analyst consensus estimate of $(4.28...
Maxim Group analyst Naz Rahman reiterates Palisade Bio (NASDAQ:PALI) with a Buy and maintains $22.5 price target.